Japan
Findings Reinforce QDENGA’s Long-Term Safety Profile and Two-Dose Vaccination Schedule QDENGA is the Longest-Studied Dengue Vaccine and the ...
November 06, 2025 | News
4DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years for dev...
November 04, 2025 | News
4DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years for dev...
November 04, 2025 | News
– Aiming to establish af-001 as a new therapeutic option for radioactive iodine (RAI)-naïve patients with differentiated thyroid cancer – ...
November 03, 2025 | News
Significantly extended survival and improved quality of life (QoL) for cancer patients achieved through autologous cell-based AIET immunotherapy...
October 28, 2025 | News
Naobios, a CDMO providing bioprocess development and GMP production of clinical batches of virus-based products, and the Tokyo Metropolitan Institute of Me...
October 27, 2025 | News
OPUSWAVE Imaging System combines OFDI and IVUS into a single catheter, providing significant potential to reduce procedural time and costs ...
October 27, 2025 | News
Collaboration will leverage AGC Biologics’ commercial manufacturing experience and proven platforms to seek regulatory approval for a therapy treat...
October 24, 2025 | News
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, announced that has entered into an exclusive ...
October 24, 2025 | News
Takeda to Receive Rights to Two Next-Generation Late-Stage Investigational Medicines, Worldwide Outside of Greater China, and an Exclusive Option to Li...
October 23, 2025 | News
THUNDERBEAT™ II features the versatility of three energy modes to support surgeons in adapting to challenging clinical conditions Olympus Corporatio...
October 22, 2025 | News
Data strongly supports advancing high dose AURN001 regenerative cell therapy for patients with corneal endothelial disease to pivotal Phase 3 trial in H1...
October 20, 2025 | News
A confirmed objective response rate of 68.2% and a disease control rate of 95.5% was observed with Daiichi Sankyo and AstraZeneca’s DATROWAY in c...
October 20, 2025 | News
PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter "PeptiDream")(Tokyo: 4587), PDRadiopharm...
October 17, 2025 | News
Most Read
Bio Jobs
News
Editor Picks